Study Summary:
A randomized, open-label, active-controlled, parallel-group, multicenter study to determine the safety and efficacy of albiglutide administered in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes mellitus.
Qualified Participants Must:
• Have type 2 diabetes
•
Be 18 to 75 years of age
•
Currently be treated with insulin, with or without oral anti-diabetic medication
Qualified Participants May Receive:
Study medication, glucometer, study related physical exams, lab tests, diet and exercise counseling and compensation for time and travel.